Table 2.
Organ supportive therapies, complications and outcomes
| Non-IAA (n = 72 (89%)) |
IAA (n = 9 (11%)) |
p value | |
|---|---|---|---|
| Organ supportive therapy | |||
| Invasive mechanical ventilation (%) | 30 (41.7) | 9 (100) | < 0.001 |
| Renal replacement therapy* (%) | 9 (12.5) | 4 (44.4) | 0.03 |
| vv-ECMO (%) | 10 (13.9) | 2 (22.2) | 0.62 |
| Vasoactive support (%) | 32 (44.4) | 8 (88.9) | 0.01 |
| Complications and outcomes | |||
| Any complication** (%) | 43 (62.0) | 7 (77.8) | 0.48 |
| ARDS (%) | 15 (20.8) | 5 (55.6) | 0.04 |
| Respiratory superinfection (%) | 20 (27.8) | 9 (100) | < 0.001 |
| ICU mortality (%) | 11 (15.3) | 3 (33.3) | 0.18 |
| In-hospital mortality (%) | 13 (18.1) | 3 (33.3) | 0.37 |
| Combined poor outcome (%) | 26 (36.1) | 9 (100) | < 0.001 |
*Includes haemodialysis and diafiltration
**Any complication includes ARDS, cardiogenic shock, stroke, multi-organ failure, delirium and other complications
Vv-ECMO veno-venous extracorporeal membrane oxygenation, ARDS acute respiratory distress syndrome, ICU intensive care unit, IAA influenza-associated aspergillosis, Non-IAA influenza infection without aspergillosis